A regulatory perspective on the role of drug interactions in
antiretroviral drug development.  Office of New Drugs, Division
of Antiviral Products, US Food and Drug Administration, Silver
Spring, Maryland 20993, USA. Current opinion in HIV and AIDS
(Impact Factor: 4.75). 06/2008; 3(3):325-9.
DOI:10.1097/COH.0b013e3282f5f509 Source: PubMed  ABSTRACT To
provide a regulatory perspective on the role of drug interaction
information in the development of antiretroviral drugs.
Additionally, this review highlights novel studies that provided
important information for the safe and effective use of
antiretroviral medications. The management of drug interactions
in HIV therapy becomes more complex with the introduction of
each new drug because many antiretroviral drugs are involved in
multiple metabolic and transporter-based interactions.
Therefore, a comprehensive preclinical evaluation to
characterize a new drug's metabolic pathway(s) followed by in-
vivo studies is critical for the safe use of combination
antiretrovir